弥可保治疗中心性浆液性脉络膜视网膜病变的临床观察  

The clinical evaluation for Methycobal in the treatment of central serous chorioretinopathy

作　　者：程凯尧[1] 

机构地区：[1]浙江省绍兴市第二医院眼科,绍兴312000

出　　处：《江西医药》2007年第11期979-981,共3页Jiangxi Medical Journal

摘　　要：目的评价弥可保治疗中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy,CSC)的疗效。方法经临床检查和眼底血管荧光造影诊断为CSC的患者86例(86眼),分为弥可保治疗组和对照组各43例(43眼),并对治疗前后的眼底、视力及眼底血管荧光造影等进行比较。结果弥可保治疗组总有效率为55.9%,视力提高率69.8%,血管造影荧光素渗漏消失率53.5%;对照组分别为23.3%、30.2%和25.6%。两者差异有统计学意义(P<0.05)。结论弥可保治疗CSC可快速修复其视网膜外层组织。Objective To observe effects of Methycobal in treatment of central serous chorioretinopathy（CSC）. Methods A total of 86 patients（86eyes） with CSC were divided into treatment group（43eyes） with Methycobal and control group（43eyes）.After treatment fundus of eye,visual acuity,and funding of fundus fluorescein angiography were compared between two groups with pretreatment.Results There was a total utility rate of 55.9% in the treatment group and 23.3% in the control group respectively.The visual acuity was improved obviously and the eyes without fluorescein leakage were more in the treatment group than control group.These results have significandy difference between two groups （P〈0.05）.Conclusion Methycobal posses obvious clinical effect in the treatment of CSC,and it could promote recovery of retinal surface layer.

关 键 词：中心性浆液性脉络膜视网膜病变 视力 眼底血管荧光造影 弥可保 

分 类 号：R774.1[医药卫生—眼科]